Tag Archive for: oncology

Simris Group Appoints Biotechnology Expert Dr. Tiffany J. Vora as Strategic Advisor

/in

Hammenhög, Sweden, July 28, 2026 — Simris Group AB (SIMRIS B) today announced the appointment of Dr. Tiffany J. Vora as a Strategic Advisor. Dr. Vora is a biotechnology scientist, entrepreneur, educator, and advisor with experience across molecular biology, genomics, biotechnology innovation, and drug discovery. Through her work with technology companies, startups, scientific organizations, and the broader innovation […]

Read more

ReBio Pharma appoints leading ocular oncologist Professor Mandeep Sagoo as Chief Medical Officer

/in

· Brings nearly three decades of clinical, translational and biotechnology experience, strengthening ReBio’s leadership team as it prepares to advance RBP-01 into the clinic · RBP-01 targets primary uveal melanoma, the most common primary eye cancer in adults and an indication with no approved therapies Turku, Finland and Geneva, Switzerland, 22 July2026 – ReBioPharma (“ReBio” […]

Read more

Poolbeg Pharma plc – Notice of Allowance received for POLB 001 Cancer Immunotherapy-induced CRS patent in Israel

/in

Continued momentum in Poolbeg’s global intellectual property strategy 21 July 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received a Notice of Allowance for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) patent application from the Israeli Patent […]

Read more

Poolbeg Pharma Plc – Placing to raise £3.5 million, Executive Chair Cathal Friel subscribes for £250,000

/in

Poolbeg Pharma Plc (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, is pleased to announce that it has raised £3.5 million (before expenses) pursuant to a placing of 58,333,328 new ordinary shares of 0.02 pence each in the capital of the Company (“Placing Shares”) with certain existing institutional and other investors (“Placing”). […]

Read more

Poolbeg Pharma plc – First Patient Dosed in the POLB 001 TOPICAL Clinical Trial

/in

Interim data remains on track for summer 2026 and partnering discussions continue to advance with multiple companies Highlights ·    First patient dosed in the POLB 001 TOPICAL clinical trial ·    Second site, University College London Hospital, activated with patient recruitment underway ·    Additional clinical sites expected to open imminently, supporting continued patient recruitment 13 July 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or […]

Read more
© Optimum Strategic Communications.